Skip to main content
Published Online:https://doi.org/10.3928/23258160-20151214-05Cited by:1

Abstract

BACKGROUND AND OBJECTIVE:

To compare immediate and delayed vitrectomy for the management of vitreous hemorrhage (VH) due to proliferative diabetic retinopathy (PDR).

PATIENTS AND METHODS:

Retrospective review of 134 eyes receiving vitrectomy for non-clearing, PDR-associated VH. Primary outcome was area under the vision curve (AUC) in patients receiving immediate (< 30 days) versus delayed (> 30 days) vitrectomy with endolaser.

RESULTS:

Forty-six eyes were included, with 17 undergoing immediate (< 30 days) vitrectomy with endolaser and 29 undergoing delayed (> 30 days) vitrectomy with endolaser. Time to vitrectomy was 14.8 days ± 8.26 days compared to 629.6 days ± 894.9 days in the immediate and delayed groups, respectively. AUC was significantly greater for patients undergoing delayed versus immediate vitrectomy (276.1 ± 0.601 logMAR*time versus 165.7 ± 0.761 logMAR*time; P < .0001). There was no difference in AUC postoperatively for delayed versus immediate surgery. Both groups required significantly less postoperative panretinal photocoagulation (P < .05). Preoperative and final visual acuities were equivalent (immediate: 1.86 ± 0.99 and 0.35 ± 0.25; P = .002; delayed: 1.71 ± 1.05 and 0.31 ± 0.34; P < .0001).

CONCLUSIONS:

Immediate vitrectomy with endolaser for PDR-associated VH (< 30 days) decreases time spent with vision loss and the need for adjunctive PRP. Modern vitrectomy is safe and may be considered earlier in VH management.

[Ophthalmic Surg Imaging Lasers Retina. 2016;47:35–41.]

  • 1.No authors listed. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol. 1990; 108(7):958–964.10.1001/archopht.1990.01070090060040

    Crossref MedlineGoogle Scholar
  • 2.Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services, 2014.

    Google Scholar
  • 3.American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013; 36(4):1033–1046.10.2337/dc12-2625

    Crossref MedlineGoogle Scholar
  • 4.Sharma S, Hollands H, Brown GC, Brown MM, Shah GK, Sharma SM. The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy. Curr Opin Ophthalmol. 2001; 12(3):230–234.10.1097/00055735-200106000-00016

    Crossref MedlineGoogle Scholar
  • 5.Gupta V, Arevalo JF. Surgical management of diabetic retinopathy. Middle East Afr J Ophthalmol. 2013; 20(4):283–292.10.4103/0974-9233.120003

    Crossref MedlineGoogle Scholar
  • 6.Ratnarajan G, Mellington F, Saldanha M, de Silva SR, Benjamin L. Long-term visual and retinopathy outcomes in a predominately type 2 diabetic patient population undergoing early vitrectomy and endolaser for severe vitreous haemorrhage. Eye (Lond). 2011; 25(6):704–708; quiz 709.10.1038/eye.2011.65

    Crossref MedlineGoogle Scholar
  • 7.Ostri C. Intraocular surgery in a large diabetes patient population: risk factors and surgical results. Acta Ophthalmol. 2014; 92 Thesis1:1–13.10.1111/aos.12364

    CrossrefGoogle Scholar
  • 8.Newman DK. Surgical management of the late complications of proliferative diabetic retinopathy. Eye (Lond). 2010; 24(3):441–449.10.1038/eye.2009.325

    Crossref MedlineGoogle Scholar
  • 9.Spraul CW, Grossniklaus HE. Vitreous hemorrhage. Surv Ophthalmol. 1997; 42(1):3–39.10.1016/S0039-6257(97)84041-6

    Crossref MedlineGoogle Scholar
  • 10.Parikh R, Shah RJ, VanHouten JP, Cherney EF. Ocular findings at initial pan retinal photocoagulation for proliferative diabetic retinopathy predict the need for future pars plana vitrectomy. Retina. 2014; 34(10):1997–2002.10.1097/IAE.0000000000000192

    Crossref MedlineGoogle Scholar
  • 11.American Society for Retina Surgeons. Preferences and Trends Survey. 2015.

    Google Scholar
  • 12.Schoenberger SD, Miller DM, Riemann CD, et al.Outcomes of 25-gauge pars plana vitrectomy in the surgical management of proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imaging. 2011; 42(6):474–480.10.3928/15428877-20110901-02

    LinkGoogle Scholar
  • 13.Gupta B, Sivaprasad S, Wong R, et al.Visual and anatomical outcomes following vitrectomy for complications of diabetic retinopathy: the DRIVE UK study. Eye (Lond). 2012; 26(4):510–516.10.1038/eye.2011.321

    Crossref MedlineGoogle Scholar
  • 14.Sima P, Zoran T. Long-term results of vitreous surgery for proliferative diabetic retinopathy. Doc Ophthalmol. 1994; 87(3):223–232.10.1007/BF01203852

    Crossref MedlineGoogle Scholar
  • 15.No authors listed. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol. 1985; 103(11):1644–1652.10.1001/archopht.1985.01050110038020

    Crossref MedlineGoogle Scholar
  • 16.Henderson JM, Ferreira F. The Interface of Language, Vision, and Action: Eye Movements and the Visual World. New York: Psychology Press; 2004:xiv,399.

    Google Scholar
  • 17.Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007; 298(8):902–916.10.1001/jama.298.8.902

    Crossref MedlineGoogle Scholar
  • 18.No authors listed. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 3. Ophthalmology. 1988; 95(10):1307–1320.10.1016/S0161-6420(88)33015-0

    Crossref MedlineGoogle Scholar
  • 19.Yeoh J, William C, Allen P, et al.Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Experiment Ophthalmol. 2008; 36(5):449–454.

    MedlineGoogle Scholar
  • 20.Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol. 2008; 246(6):837–842.10.1007/s00417-008-0774-y

    Crossref MedlineGoogle Scholar
  • 21.Ushida H, Kachi S, Asami T, Ishikawa K, Kondo M, Terasaki H. Influence of preoperative intravitreal bevacizumab on visual function in eyes with proliferative diabetic retinopathy. Ophthalmic Res. 2013; 49(1):30–36.10.1159/000324135

    Crossref MedlineGoogle Scholar
  • 22.Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye (Lond). 2009; 23(1):108–111.10.1038/sj.eye.6702983

    Crossref MedlineGoogle Scholar
  • 23.Arevalo JF, Maia M, Flynn H, et al.Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008; 92(2):213–216.10.1136/bjo.2007.127142

    Crossref MedlineGoogle Scholar
  • 24.No authors listed. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995; 102(4):647–661.10.1016/S0161-6420(95)30973-6

    Crossref MedlineGoogle Scholar
  • 25.No authors listed. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol. 1995; 113(1):36–51.10.1001/archopht.1995.01100010038019

    Crossref MedlineGoogle Scholar
  • 26.Agarwal A, Soliman MK, Sepah YJ, Do DV, Nguyen QD. Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics. Pharmgenomics Pers Med. 2014; 7:399–409.

    MedlineGoogle Scholar

We use cookies on this site to enhance your user experience. For a complete overview of all the cookies used, please see our privacy policy.

×